Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Damla, Uludağ"'
Autor:
Damla Uludağ, Sadık Bay, Bilgesu Onur Sucu, Özgecan Şavluğ İpek, Thomas Mohr, Mustafa Güzel, Nihal Karakaş
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Change in the energy metabolism of cancer cells, which display significant differences compared to normal cells, is a rising phenomenon in developing new therapeutic approaches against cancers. One of the metabolic enzymes, hexokinase-II (HK-II) is i
Externí odkaz:
https://doaj.org/article/2f2e98f9bf9a49a594df53503809c75d
Autor:
Nihal Karakaş, Süleyman Üçüncüoğlu, Damla Uludağ, Birnur Sinem Karaoğlan, Khalid Shah, Gürkan Öztürk
Publikováno v:
Cells, Vol 11, Iss 3, p 465 (2022)
The novel pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Mesenchymal stem cells (MSCs) are currently utilized in clinics for pulmonary inflammatory diseases, including acute respira
Externí odkaz:
https://doaj.org/article/174e434c26244d92a40a5ece1fd256a0
Autor:
Nihal KARAKAŞ, Mehmet Evren OKUR, Tuğba SAĞIR, Damla ULUDAĞ, Derya Çiçek POLAT, Ayşe Esra KARADAĞ
Publikováno v:
Ankara Universitesi Eczacilik Fakultesi Dergisi. :781-791
Objective: Vaccinium myrtillus L. fruits are consumed as food. This research was aimed to evaluate V. myrtillus methanol extract antioxidant and cytotoxic activities and determine its anti-cancer potential to further study against gastric cancer. Mat
Autor:
Damla, Uludağ, Sadık, Bay, Bilgesu Onur, Sucu, Özgecan, Şavluğ İpek, Thomas, Mohr, Mustafa, Güzel, Nihal, Karakaş
Publikováno v:
Frontiers in pharmacology. 13
Change in the energy metabolism of cancer cells, which display significant differences compared to normal cells, is a rising phenomenon in developing new therapeutic approaches against cancers. One of the metabolic enzymes, hexokinase-II (HK-II) is i
Autor:
Damla, Uludağ, Nihal, Karakaş
Publikováno v:
Anticancer research. 41(7)
Pseudomonas exotoxin (PE) is one of the most widely used toxins in the construction of therapeutic fusion proteins in pre-clinical studies followed by phase trials. In principle, PE acts by blocking protein synthesis through catalyzing the inactivati